The Osteosarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Osteosarcoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Osteosarcoma Market.
Some of the key takeaways from the Osteosarcoma Pipeline Report:
Companies across the globe are diligently working toward developing novel Osteosarcoma treatment therapies with a considerable amount of success over the years.
Osteosarcoma companies working in the treatment market are Dana-Farber Cancer Institute, MedPacto, Inc., K-Group, Beta, Inc., H. Lee Moffitt Cancer Center, Hansoh BioMedical R&D Company, Ipsen, UNICANCER, Adaptimmune, M.D. Anderson Cancer Center, and others, are developing therapies for the Osteosarcoma treatment
Emerging Osteosarcoma therapies in the different phases of clinical trials are- Olaparib, Vactosertib, ZN-c3, Nivolumab, HS-20093, Cabozantinib, cisplatin, Afamitresgene autoleucel, Aldesleukin, and others are expected to have a significant impact on the Osteosarcoma market in the coming years.
In April 2024, Lisata Therapeutics has received orphan drug designation from the FDA for its investigational agent LSTA1 (CEND-1) to treat pediatric and adult patients with osteosarcoma.
Osteosarcoma Overview
Osteosarcoma is a type of bone cancer that originates in the cells that form bones. It is the most common type of cancer that starts in the bones, primarily affecting children, teenagers, and young adults.
Get a Free Sample PDF Report to know more about Osteosarcoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/osteosarcoma-pipeline-insight
Emerging Osteosarcoma Drugs Under Different Phases of Clinical Development Include:
Olaparib: Dana-Farber Cancer Institute
Vactosertib: MedPacto, Inc.
ZN-c3: K-Group, Beta, Inc.
Nivolumab: H. Lee Moffitt Cancer Center
HS-20093: Hansoh BioMedical R&D Company
Cabozantinib: Ipsen
cisplatin: UNICANCER
Afamitresgene autoleucel: Adaptimmune
Aldesleukin: M.D. Anderson Cancer Center
Osteosarcoma Route of Administration
Osteosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Osteosarcoma Molecule Type
Osteosarcoma Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Osteosarcoma Pipeline Therapeutics Assessment
Osteosarcoma Assessment by Product Type
Osteosarcoma By Stage and Product Type
Osteosarcoma Assessment by Route of Administration
Osteosarcoma By Stage and Route of Administration
Osteosarcoma Assessment by Molecule Type
Osteosarcoma by Stage and Molecule Type
DelveInsight’s Osteosarcoma Report covers around 30+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Osteosarcoma product details are provided in the report. Download the Osteosarcoma pipeline report to learn more about the emerging Osteosarcoma therapies
Some of the key companies in the Osteosarcoma Therapeutics Market include:
Key companies developing therapies for Osteosarcoma are – Pfizer Inc., Recordati Group, Takeda Pharmaceutical Company, Amgen, Baxter, Bayer AG, Hikma Pharmaceuticals, Johnson & Johnson, Novartis AG, Debiopharm, Eli Lilly and Company, Atlanthera, Spectrum Pharmaceuticals Inc., and others.
Osteosarcoma Pipeline Analysis:
The Osteosarcoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Osteosarcoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteosarcoma Treatment.
Osteosarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Osteosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteosarcoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Osteosarcoma drugs and therapies
Osteosarcoma Pipeline Market Strengths
The rise in the incidence of osteosarcoma
Improvement of treatment over the years along with newly updated guidelines
Various immunotherapies such as PD-L1 inhibitors and CTLA4 inhibitors are under investigation for osteosarcoma
Osteosarcoma Pipeline Market Opportunities
Genetic and other disease-related biomarkers are not much explored in drug development
Lack of approved drugs for chemo-resistant disease and maintenance therapy
Scope of Osteosarcoma Pipeline Drug Insight
Coverage: Global
Key Osteosarcoma Companies: Dana-Farber Cancer Institute, MedPacto, Inc., K-Group, Beta, Inc., H. Lee Moffitt Cancer Center, Hansoh BioMedical R&D Company, Ipsen, UNICANCER, Adaptimmune, M.D. Anderson Cancer Center, and others
Key Osteosarcoma Therapies: Olaparib, Vactosertib, ZN-c3, Nivolumab, HS-20093, Cabozantinib, cisplatin, Afamitresgene autoleucel, Aldesleukin, and others
Osteosarcoma Therapeutic Assessment: Osteosarcoma current marketed and Osteosarcoma emerging therapies
Osteosarcoma Market Dynamics: Osteosarcoma market drivers and Osteosarcoma market barriers
Request for Sample PDF Report for Osteosarcoma Pipeline Assessment and clinical trials
Table of Contents
1. Osteosarcoma Report Introduction
2. Osteosarcoma Executive Summary
3. Osteosarcoma Overview
4. Osteosarcoma- Analytical Perspective In-depth Commercial Assessment
5. Osteosarcoma Pipeline Therapeutics
6. Osteosarcoma Late Stage Products (Phase II/III)
7. Osteosarcoma Mid Stage Products (Phase II)
8. Osteosarcoma Early Stage Products (Phase I)
9. Osteosarcoma Preclinical Stage Products
10. Osteosarcoma Therapeutics Assessment
11. Osteosarcoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Osteosarcoma Key Companies
14. Osteosarcoma Key Products
15. Osteosarcoma Unmet Needs
16 . Osteosarcoma Market Drivers and Barriers
17. Osteosarcoma Future Perspectives and Conclusion
18. Osteosarcoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
